The US Food and Drug Administration has approved Foundayo, a daily oral medication for weight loss developed by Eli Lilly – the same company behind the popular injectable Zepbound. This marks a significant shift in the obesity treatment landscape, offering patients a new option beyond injections.
The Rise of GLP-1 Medications
Foundayo belongs to a class of drugs called GLP-1s, which includes established medications like Ozempic and Wegovy. These drugs work by mimicking a natural hormone that regulates blood sugar, suppresses appetite, and promotes feelings of fullness. The approval of Foundayo follows Novo Nordisk’s recent FDA clearance for a pill version of Wegovy in December, signaling a race among pharmaceutical companies to develop convenient oral weight-loss options.
Why Pills Matter
Injectable GLP-1 drugs have faced manufacturing shortages due to high demand, stretching from late 2022 through early 2025. Pills are easier and cheaper to produce, potentially alleviating supply issues and making treatment more accessible. Beyond logistics, some patients may prefer pills to injections for psychological or practical reasons. As Eli Lilly executive Ken Custer notes, “Some patients just don’t want to take an injection… for them, an injection signifies that their condition is more severe than they feel it is.”
Trial Results and Efficacy
Clinical trials show Foundayo leads to significant weight loss. Participants taking the highest dose over 18 months lost an average of 27 pounds (12.4% of body weight), compared to just 2 pounds lost by the placebo group. While effective, it doesn’t match the 20%+ weight reduction achieved by Lilly’s injectable tirzepatide (Mounjaro and Zepbound). Novo Nordisk’s Wegovy pill demonstrated an average 13.6% weight loss over 16 months in trials. No direct comparison tests between Foundayo and the Wegovy pill have been conducted yet.
Switching From Injections
Lilly also studied patients switching from injectable GLP-1s to Foundayo, finding they maintained most of their weight loss. Those who switched from Wegovy regained an average of 2 pounds, while those switching from Zepbound gained 11 pounds. The active ingredient, orforglipron, is also under investigation for treating type 2 diabetes, sleep apnea, osteoarthritis, and other conditions.
Availability and Speed of Approval
Foundayo is now available through LillyDirect, with broader retail and telehealth distribution planned shortly. The FDA expedited its review under a new pilot program, approving it in just 50 days – significantly faster than the typical 6-10 months. This suggests a heightened priority for obesity treatments among regulators.
The approval of Foundayo marks a step towards more accessible and convenient weight-loss options, but its long-term efficacy and potential side effects will need further study. It also highlights a broader trend of regulatory acceleration for drugs addressing major public health concerns.
